GlobeNewswire·Nov 10, 2026, 4:02 PM ET

Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates

STXS

Stereotaxis reported third-quarter 2026 revenue of $8.9 million, a 20% increase from $7.5 million in the prior year period.
System revenue reached $3.0 million, up 60% year-over-year, driven by partial revenue recognition from the first GenesisX system in the US, the first Genesis system in China, & Synchrony systems.
Recurring revenue totaled $5.9 million, a 6% increase from the prior year, reflecting growth in robotically-navigated catheters offset by supply shortages.
The company entered the fourth quarter with a $1.9 million backlog of disposable orders that were not converted to revenue due to supply constraints.
Gross margin for the quarter was 45%, with recurring revenue margins at 59% & system revenue margins at 15%.
Operating expenses were $10.4 million, including $1.3 million in non-cash charges, while adjusted operating expenses were $9.1 million.
The company reported a net loss of $6.5 million for the quarter, compared to $6.6 million in the prior year period.
Cash & cash equivalents stood at $4.0 million as of September 30, 2026.
Stereotaxis announced a convertible note financing of up to $24 million, with an initial $12 million closing & an additional $12 million available after regulatory milestones.
The firm acquired Robocath & announced a collaboration with Canon to expand its endovascular surgical platform.
Forward-looking expectations include growing recurring revenue, more consistent capital sales, & a pathway to cash-flow profitability within the next year.
Adjusted operating expenses are projected to approximate $8 million per quarter going forward.

Company: Stereotaxis, Inc.
Keywords: NYSE:STXS, Stereotaxis, Inc., FINANCIAL NEWS, INVESTMENT, HEALTHCARE TECHNOLOGY